DRKS00019856已完成不适用
10-year tolvaptan in ADPKD - A patient-based center evaluation
Otsuka Pharma GmbH0 个研究点目标入组 13 人开始时间: 2020年1月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Adult ADPKD patients who have participated in both the TEMPO 3: 4 (Verum Group) and TEMPO 4: 4 trials and are currently receiving treatment with Jinarc® (tolvaptan).
排除标准
- •Patients who do not meet the inclusion criteria.
研究者
相似试验
已完成
3 期
Tolvaptan Extension Study in Participants With ADPKDAutosomal Dominant Polycystic Kidney Disease (ADPKD)NCT01214421Otsuka Pharmaceutical Development & Commercialization, Inc.1,083
招募中
不适用
The German ADPKD Tolvaptan Treatment RegistryADPKD (Autosomal Dominant Polycystic Kidney Disease)NCT02497521University of Cologne2,000
已完成
不适用
Tolvaptan Intervention study and Genetic mutation of AutosomalDominant Polycystic Kidney DiseaseADPKDJPRN-jRCTs031180259Horie Shigeo
进行中（未招募）
1 期
Effect of tolvaptan on renal blood flow and glomerular filtration in patients with polycystic kidney diseaseAdult dominant polycystic kidney disease (ADPKD)MedDRA version: 20.0Level: LLTClassification code 10036046Term: Polycystic kidney, autosomal dominantSystem Organ Class: 100000004850EUCTR2015-001903-30-DKDepartment of Medical Research30
已完成
3 期
A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]Autosomal Dominant Polycystic Kidney Disease （ADPKD)NCT01280721Otsuka Pharmaceutical Co., Ltd.135